Tornike Mamuladze

Tornike Mamuladze

Auto-generated profile, based on publicly available information

Tornike Mamuladze

Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in Science
Verified
Journal Article
Closed access
PDF file
ACAndrea Cugurra
Andrea Cugurra
TMTornike Mamuladze
Tornike Mamuladze
JRJustin Rustenhoven
Justin Rustenhoven
TDTaitea Dykstra
Taitea Dykstra
GBGiorgi Beroshvili
Giorgi Beroshvili
JKJonathan Kipnis
Jonathan Kipnis
Getting around the blood–brain barrier: The meninges comprise three membranes that surround and protect the central nervous system (CNS). Recent studies have noted the existence of myeloid cells resident there, but little is known about their ontogeny and function, and whether other meningeal immune cell populations have important roles remains unclear (see the Perspective by Nguyen and Kubes). Cugurra et al. found in mice that a large proportion of continuously replenished myeloid cells in the dura mater are not blood derived, but rather transit from cranial bone marrow through specialized channels. In models of CNS injury and neuroinflammation, the authors demonstrated that these myeloid cells have an immunoregulatory phenotype compared with their more inflammatory blood-derived counterparts. Similarly, Brioschi et al. show that the meninges host B cells that are also derived from skull bone marrow, mature locally, and likely acquire a tolerogenic phenotype. They further found that the brains of aging mice are infiltrated by a second population of age-associated B cells, which come from the periphery and may differentiate into autoantibody-secreting plasma cells after encountering CNS antigens. Together, these two studies may inform future treatment of neurological diseases. Science , abf7844, abf9277, this issue p. eabf7844 , p. eabf9277 ; see also abj8183, p. 396

27 January 2021 in Cell
Verified
Journal Article
Closed access
JRJustin Rustenhoven
Justin Rustenhoven
ADAntoine Drieu
Antoine Drieu
TMTornike Mamuladze
Tornike Mamuladze
KLKalil Alves de Lima
Kalil Alves de Lima
TDTaitea Dykstra
Taitea Dykstra
JKJonathan Kipnis
Jonathan Kipnis

9 November 2022 in Nature
Verified
Journal Article
Open access
PDF file
ADAntoine Drieu
Antoine Drieu
SDSiling Du
Siling Du
SSSteffen Storck
Steffen Storck
JRJustin Rustenhoven
Justin Rustenhoven
ZPZachary Papadopoulos
Zachary Papadopoulos
JKJonathan Kipnis
Jonathan Kipnis
Macrophages are important players in the maintenance of tissue homeostasis1. Perivascular and leptomeningeal macrophages reside near the central nervous system (CNS) parenchyma2, and their role in CNS physiology has not been sufficiently well studied. Given their continuous interaction with the cerebrospinal fluid (CSF) and strategic positioning, we refer to these cells collectively as parenchymal border macrophages (PBMs). Here we demonstrate that PBMs regulate CSF flow dynamics. We identify a subpopulation of PBMs that express high levels of CD163 and LYVE1 (scavenger receptor proteins), closely associated with the brain arterial tree, and show that LYVE1+ PBMs regulate arterial motion that drives CSF flow. Pharmacological or genetic depletion of PBMs led to accumulation of extracellular matrix proteins, obstructing CSF access to perivascular spaces and impairing CNS perfusion and clearance. Ageing-associated alterations in PBMs and impairment of CSF dynamics were restored after intracisternal injection of macrophage colony-stimulating factor. Single-nucleus RNA sequencing data obtained from patients with Alzheimer’s disease (AD) and from non-AD individuals point to changes in phagocytosis, endocytosis and interferon-γ signalling on PBMs, pathways that are corroborated in a mouse model of AD. Collectively, our results identify PBMs as new cellular regulators of CSF flow dynamics, which could be targeted pharmacologically to alleviate brain clearance deficits associated with ageing and AD.

17 March 2022 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
JMJose A. Mazzitelli
Jose A. Mazzitelli
LSLeon C. D. Smyth
Leon C. D. Smyth
KCKevin A. Cross
Kevin A. Cross
TDTaitea Dykstra
Taitea Dykstra
JSJerry Sun
Jerry Sun
JKJonathan Kipnis
Jonathan Kipnis

21 January 2026 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
SDSiling Du
Siling Du
KNKhai M. Nguyen
Khai M. Nguyen
AAAlina Ulezko Antonova
Alina Ulezko Antonova
JFJose L. Fachi
Jose L. Fachi
PRPatrick Fernandes Rodrigues
Patrick Fernandes Rodrigues
SBSimone Brioschi
Simone Brioschi

2 December 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
LSLeon Smyth
Leon Smyth
DVDaan Verhaege
Daan Verhaege
ESElio Standen-Bloom
Elio Standen-Bloom
YWYue Wu
Yue Wu
YGYiming Gan
Yiming Gan
JKJonathan Kipnis
Jonathan Kipnis
Alzheimer’s disease (AD) is characterized by the accumulation of extracellular aggregated amyloid beta, resulting from impaired waste clearance. We recently identified new cerebrospinal fluid (CSF) efflux structures termed arachnoid cuff exit (ACE) points and speculated that these may be impacted in AD, leading to impaired waste clearance function. Using 5XFAD mice, we found progressive amyloidosis of bridging veins at ACE points. Indeed, in 5XFAD mice, there is impaired CSF efflux to the dura mater, impaired CSF flow along bridging veins, and impaired blood flow through bridging veins. These observations suggest that ACE point amyloidosis plays a role in waste clearance dysfunction in AD. In postmortem human samples, we also found striking amyloidosis of the bridging veins of individuals with AD. Moreover, in human AD specimens, there was prominent bridging vein structural degeneration, indicating advanced pathology and stronger deficits in humans. We propose that bridging vein amyloidosis is an underrecognized pathophysiological correlate of AD that may impair CSF efflux, intracranial pressure, vascular reactivity, and vascular integrity.